BioSpace News Archive

FDA

BMS CAR-T Therapy Wins FDA Approval for Expanded Use in Follicular Lymphoma

Following back-to-back approvals in lymphocytic leukemia, Bristol Myers Squibb’s CAR-T therapy Breyanzi on Wednesday won the FDA’s green light for relapsed or refractory follicular lymphoma.

May 16, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Roche Sees Early ROI on $2.7B Carmot Buy with Phase I Data for Obesity Candidate

Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study.

May 16, 2024
·
2 min read
·
Tristan Manalac
Business

Galapagos Partners with Blood Centers of America to Decentralize CAR-T Production

Belgian biotech Galapagos is teaming with Blood Centers of America to help deploy its decentralized CAR-T therapy manufacturing platform closer to treatment centers across the U.S.

May 16, 2024
·
2 min read
·
Tristan Manalac
Policy

Sanders Warns Weight-Loss Drugs Could Bankrupt US Healthcare System

A Senate health committee report published Wednesday forecasts spending on prescription drugs to hit $1 trillion a year in 2031, unless the prices of GLP-1 medicines such as Novo Nordisk’s Wegovy are cut.

May 16, 2024
·
2 min read
·
Nick Paul Taylor
Deals

J&J Buys Proteologix for $850M, Bispecific Antibodies for Atopic Dermatitis

Johnson & Johnson announced Thursday it is paying $850 million in cash, plus a potential milestone payment, for privately held biotech Proteologix and its atopic dermatitis-focused bispecific antibody candidates.

May 16, 2024
·
2 min read
·
Kate Goodwin
Drug Development

Lilly’s Weekly Insulin Scores Late-Stage Win as Race With Novo Heats Up

Eli Lilly’s efsitora alfa, which is meant to be taken weekly instead of multiple times a day, demonstrated non-inferior A1C reduction in a Phase III trial compared to Novo Nordisk’s daily insulin.

May 16, 2024
·
2 min read
·
Tyler Patchen
FDA

ICER Finds ‘Substantial Uncertainties’ in Lykos’ MDMA Trials Ahead of Adcomm

With a June 4 FDA advisory committee meeting looming, the Institute for Clinical and Economic Review has raised concerns about Lykos Therapeutics’ trials of its MDMA-assisted therapy in post-traumatic stress disorder.

May 16, 2024
·
2 min read
·
Tristan Manalac
Business

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the interim report for the three months ended March 31, 2024, and provided a corporate update.

May 16, 2024
·
10 min read
Drug Development

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

Genentech, a member of the Roche Group, announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes.

May 16, 2024
·
4 min read
Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

ANGLE plc is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer patients.

May 16, 2024
·
5 min read